Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell Carcinoma

NCT05517330 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

BIOLOGICAL: Tislelizumab
DRUG: Afatinib

Sponsor

West China Hospital